Healthcare Distribution Alliance – Patients Move Us.

+ About
- Role of Distributors
- Membership
- HDA History
- Member Directory
- Staff Directory
- Industry Recognition
- Executive Committee
- Mission and Values
- Board of Directors
- Join HDA
- Councils and Committees
- Careers
- About
  
  Information regarding HDA's history, leadership, mission, values and staff.
+ Issues
- Pharmaceutical Traceability
- Distributor Licensure
- Importation of Prescription Medicines
- Drug Shortages
- Prescription Drug Abuse and Diversion
- Emergency Preparedness
- Taxes
- Grassroots Advocacy
- Reimbursement
- Issues
  
  HDA reviews key priority issues and advocates on behalf of its pharmaceutical distributor members for standards, public policies and business processes that ensure a safe and efficient supply chain.
+ Events
- Distribution Management Conference and Expo
- PCSC Educational Seminar
- Business and Leadership Conference
- Webinars
- Traceability Seminar
- Speaker Resource Center
- Events
  
  HDA regularly brings members and key healthcare supply chain stakeholders together to share industry information, learn about best practices, and be introduced to new products and services.
+ News
- Press Releases
- Blog
- Testimony
- HDA in the News
  
  Press releases, public testimony executive statements and information on HDA's efforts on behalf of pharmaceutical distributors and the supply chain.
+ Resources
- Publications
- Professional Development
- Vital Link Toolkit
- PCSC
- Webinars
- Annual Report
- Allied Against Opioid Abuse
- Resources
  
  HDA and the HDA Research Foundation produce a variety of resources to enhance the value of the supply chain and increase industry knowledge.

Share Print

Home | News | HDA Blog | Archives

HDA Blog

May 2017 Archives

HDA and NACDS Call on Congress to Protect Patient Safety by Rejecting Drug Importation Proposals

Posted 05/08/2017

In an opinion piece published today in the Capitol Hill newspaper, The Hill, HDA and NACDS called on members of Congress to honor its commitment to protecting patients and the safety of the supply chain by rejecting any proposal that would call for the importation of prescription drugs from foreign markets.